Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 86.27

+6.0%

Jan 7 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2209)	2/1/2008 1:41:26 PM
From: Jibacoa	of 3722

BAYRY Is starting to close its Jan22 DG bigcharts.marketwatch.com Its anti-coagulant Xarelto seems to be a promising products in late-stage development. BAYRY lately has increased its reliance on pharmaceuticals. Its Xarelto's PIII data released late last Yr.,showed it to be more effective than SNLF.L's Lovenox, at preventing phlebothrombosis after orthopedic surgery. BAYRY has filed an NDA with the EMEA & plans for possible launch in 2009, it also plans to file an NDA to the FDA in 2008.(JNJ has marketing rights for the U.S.)It is expected that on approval, the 1st Yr. post-launch sales could total $120M with a much larger amount if Xarelto can be approved for active treatment in AF & DVT. Back in Sep., BAYRY received FDA approval for expanded labeling of its Campath for treatment of B-cell CLL. The stock is trading around 3.70xBV with a +CF of about $7.80 The stock has 4Qs of double digit improvements on revenues & earnings. The EE for 2007 are around $5.34 about 30% > the $4.11 in 2006 & for 2008 another 15% improvement is expected. BAYRY seems to have support at the $75 level & to have a good chance of retesting its Jan 8 H at $96.83 <g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next